Follow us on Twitter
twitter icon@FreshPatents


Endothelial Dysfunction patents

      

This page is updated frequently with new Endothelial Dysfunction-related patent applications.




 Multifunctional nitroxide derivatives and uses thereof patent thumbnailMultifunctional nitroxide derivatives and uses thereof
Multifunctional nitroxide derivatives contain a potassium channel opener and a reactive oxygen species (ros) degradation catalyst that can act as an anti-oxidant. Pharmaceutical compositions can include the derivatives.
Radikal Therapeutics Inc


 Method of therapy and diagnosis of endothelial dysfunction patent thumbnailMethod of therapy and diagnosis of endothelial dysfunction
The invention discloses a method of therapy of endothelial dysfunction, by administering microrna let-7g to a subject in need, wherein the microrna let-7g inhibits smad2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis.. .
Kaohsiung Medical University


 Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide patent thumbnailMethods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition comprising nicotinamide mononucleotide and a pharmaceutical excipient to a subject.
The Regents Of The University Of Colorado, A Body Corporate


 Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction patent thumbnailCollagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.. .
Purdue Research Foundation


 Dietary compositions for reducing blood glucose levels and for weight management patent thumbnailDietary compositions for reducing blood glucose levels and for weight management
The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.


 Apolipoprotein a-i mimics patent thumbnailApolipoprotein a-i mimics
Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.. .
Cerenis Therapeutics Holding Sa


 Combined agent for cell therapy of corneal endothelial cell patent thumbnailCombined agent for cell therapy of corneal endothelial cell
The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin ii-specific inhibitor. More specifically, the myosin ii-specific inhibitor is blebbistatin.
Senju Pharmaceutical Co., Ltd.


 Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders patent thumbnailTherapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive cns noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive cns noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens..
Veroscience Llc


 Treatment of diseases of endothelial dysfunction and inflammation patent thumbnailTreatment of diseases of endothelial dysfunction and inflammation
The present disclosure provides a method for treating or preventing endothelial dysfunction in a subject, the method comprising systemically administering to the subject a population of population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.. .

 Agonists of ddah1 for treating endothelial dysfunction patent thumbnailAgonists of ddah1 for treating endothelial dysfunction
The present invention derives from the finding that expression of ddah1 is heavily post-transcriptionally regulated by micrornas. By preventing or blocking the interaction between such micrornas and the ddah1 mrna, the production of ddah1 protein can be increased.
Ucl Business Plc


Methods of treating atherosclerosis

Certain embodiments of the invention provide a method of treating endothelial dysfunction, cardiovascular disease and/or atherosclerosis in a mammal, comprising administering an effective amount of a micro-rna-204-5p inhibitor to the mammal.. .
University Of Iowa Research Foundation

Molecular targets for cardiovascular disease

The invention relates to methods and compositions for treating and preventing cardiovascular disease, including but not limited to treating and preventing endothelial dysfunction in subjects having hyperhomocysteinemia, hyperglycemia, or a combination of hyperhomocysteinemia and hyperglycemia. As endothelial dysfunction is an indicator for atherosclerosis and cardiovascular disease, this treatment has general impact for early prevention and treatment for all cardiovascular disease.
Temple University-of The Commonwealth System Of Higher Education

Prodrugs of multifunctional nitroxide derivatives and uses thereof

Prodrugs of compounds comprise a nitric oxide donor and a reactive oxygen species (ros) degradation catalyst, in particular, 1-pyrrolidinyloxy, 1-piperidinyloxy, and 1-azepanyloxy derivatives, and pharmaceutical compositions thereof. These compounds and pharmaceutical compositions are useful in prevention, treatment or management of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction..
Radikal Therapeutics Inc.

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis.
Oklahoma Medical Research Foundation

Multifunctional nitroxide derivatives and uses thereof

Multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ros) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them are provided. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction..
Radikal Therapeutics Inc

Compositions and methods for the treatment of metabolic diseases

The invention relates to the compounds of formula i, formula ii and formula iii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, formula ii or formula iii; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Synergistic anti-inflammatory compositions comprising boswellia serrata extract

The present invention discloses synergistic nutraceutical or pharmaceutical or dietary supplement anti-inflammatory compositions comprising therapeutically effective combination of an extract selectively enriched in 3-o-acetyl-1 1-keto-β-boswellic acid (akba) derived from boswellia serrata and boswellia serrata non-acidic resin extract (bnre). The composition(s) can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, endothelial dysfunction and the like.

Vasoprotective and cardioprotective antidiabetic therapy

The present invention relates to certain dpp-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such dpp-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.. .
Boehringer Ingelheim International Gmbh

Apolipoprotein a-i mimics

Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.. .
Cerenis Therapeutics Holding Sa

Method of therapy and diagnosis of endothelial dysfunction

The invention discloses a method of therapy of endothelial dysfunction, by administering microrna let-7g to a subject in need, wherein the microrna let-7g inhibits smad2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis.. .
Kaohsiung Medical University

In situ gel loaded with phosphodiesterase type v inhibitors nanoemulsion

The in situ gel loaded with phosphodiesterase type v (pde5) inhibitors nanoemulsion was prepared using an innovative approach to reformulate the pde5 inhibitors in a nanoemulsion, and then loading the nanoemulsion into an in situ gel base. These preparations are administered by intramuscular injection in order to give a depot effect for a period of time that exceeds 15 days.
King Abdulaziz University

Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof

The present invention concerns methods for treating and preventing endothelial dysfunction and related disorders, including, for example, pulmonary arterial hypertension, using bardoxolone methyl or analogs thereof.. .
Reata Pharmaceuticals, Inc.

Organic compounds

Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula i can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome x, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.

Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders

The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive cns noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive cns noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens..

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis.

Methods and compositions for the treatment of migraine headaches

The present invention is related to compositions and methods for treating or reducing the likelihood of a migraine, reducing the severity of migraine, reducing the frequency of migraines, reducing the duration of migraine, and ameliorating the symptoms of a migraine. The methods and compositions of the present invention may also be used to treat or prevent a condition characterized by increased cardiovascular risk or endothelial dysfunction and musculoskeletal symptoms..

Method and device for detecting and assessing reactive hyperemia using segmental plethysmography

A method for measuring reactive hyperemia in a subject is disclosed. The method includes performing a first segmental cuff plethysmography to generate a baseline arterial compliance curve and/or a baseline pressure-area (p-a) curve, performing a second segmental cuff plethysmography to generate a hyperemic arterial compliance curve and/or a hyperemic p-a curve, and calculating an area between the baseline and the hyperemic curves.

Method and device for detecting and assessing reactive hyperemia using segmental plethysmography

A method for measuring reactive hyperemia in a subject is disclosed. The method includes performing a first segmental cuff plethysmography to generate a baseline arterial compliance curve and/or a baseline pressure-area (p-a) curve, performing a second segmental cuff plethysmography to generate a hyperemic arterial compliance curve and/or a hyperemic p-a curve, and calculating an area between the baseline and the hyperemic curves.

Methods and compositions for detecting and modulating o-glycosylation

The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction.



Endothelial Dysfunction topics:
  • Endothelial Dysfunction
  • Endothelial
  • Dysfunction
  • Hypertension
  • Cardiovascular Disease
  • Vascular Disease
  • Cardiovascular
  • Myocardial Infarction
  • Atherosclerosis
  • Restenosis
  • Infarction
  • Osteoporosis
  • Nephropathy
  • Congestive Heart Failure
  • Steoporosis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Endothelial Dysfunction for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Endothelial Dysfunction with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3165

    file did exist - 1708

    2 - 1 - 29